Skip to main content

Recombinant Human VISTA/B7-H5/PD-1H Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 7126-B7

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
7126-B7-01M
7126-B7-050

Key Product Details

Source

NS0

Accession #

Structure / Form

Disufide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human VISTA/B7-H5/PD-1H protein
Human VISTA/B7-H5/PD-1H
(Phe33-Ala194)
Accession # AAH20568
IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Phe33

Predicted Molecular Mass

44.8 kDa (monomer)

SDS-PAGE

64-75 kDa, reducing conditions

Activity

Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes.
The ED50 for this effect is 1-6 μg/mL.

Reviewed Applications

Read 1 review rated 4 using 7126-B7 in the following applications:

Scientific Data Images for Recombinant Human VISTA/B7-H5/PD-1H Fc Chimera Protein, CF

Recombinant Human VISTA/B7-H5/PD-1H Fc Chimera Protein Bioactivity

Recombinant Human VISTA/B7-H5/PD-1H Fc Chimera Protein Bioactivity

Recombinant Human VISTA/B7-H5/PD-1H Fc Chimera (Catalog # 7126-B7) inhibits anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is 1-6 μg/mL.

Formulation, Preparation and Storage

7126-B7
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 200 μg/mL in PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VISTA/B7-H5/PD-1H

VISTA (V-domain immunoglobulin suppressor of T cell activation) is an immune checkpoint receptor expressed primarily on the surface of hematopoietic cells. Specifically, VISTA is expressed on naïve CD4+ T cells and regulatory T cells (1). And it is up regulated in vivo on activated monocytes and dendritic cells (2). VISTA inhibits CD4+ and CD8+ T cell proliferation, and their production of the proinflammatory cytokines IL 2 and IFN gamma (1). VISTA protein is also observed on the surface of cancer cells and attenuates the anti tumor immune response enabling tumor progression (1). In the autoimmune disease model EAE, VISTA limits disease progression by downregulating the overactive immune system (1). VISTA, also known as B7 H5, PD-1H, Platelet receptor Gi24, Dies1, and SISP1, is a 55 65 kDa transmembrane glycoprotein with homology to B7 like immune co stimulatory molecules (3, 4). The mature human VISTA protein contains a 162 amino acid extracellular domain (ECD) with one V type Ig like domain, a 21 aa transmembrane segment, and a 96 aa cytoplasmic domain. Within the ECD, human VISTA shares 70% and 67% amino acid sequence identity with mouse and rat VISTA, respectively (5). The 30 kDa ECD can be shed by MT1 MMP, with a 25 30 kDa fragment remaining in the membrane (5). VISTA promotes both MT1 MMP expression and the MT1 MMP mediated activation of MMP 2 (5). VISTA supports the differentiation of embryonic stem cells (ESC) and enhances BMP 4 induced signaling in ESC but is also down regulated following BMP 4 exposure (2, 6). It binds to BMP 4 directly and also associates with the type I BMP receptor Activin RIB/ALK 4 (2, 6). The identification of a binding partner for VISTA proved elusive for many years until two 2019 publications identified two distinct ligands for VISTA, VSIG-3 and PSGL-1 (7, 8). Both ligands are expressed on T cells and blocking antibodies to VISTA have been shown to reverse immune suppression making VISTA a potential therapeutic target for cancer (7, 8).

References

  1. Wang, L. et al. (2011) J. Exp. Med. 208:577. 
  2. Parisi, S. et al. (2012) FASEB J. 26:3957. 
  3. Flajnik, M.F. et al. (2012) Immunogenetics 64:571. 
  4. Wilcox, R.A. et al. (2012) Eur. J. Haematol. 88:465. 
  5. Sakr, M.A. et al. (2010) Cancer Sci. 101:2368. 
  6. Aloia, L. et al. (2010) J. Biol. Chem. 285:7776. 
  7. Wang, J. et al. (2019) Immunology. 156:74. 
  8. Johnston, R.J. et al. (2019) Nature. 574:565.

Alternate Names

4632428N05Rik, B7-H5, C10orf54, Dies1, Gi24, PD-1H, PD1H, SISP1, VSIR

Entrez Gene IDs

64115 (Human); 74048 (Mouse); 690899 (Rat); 102116468 (Cynomolgus Monkey)

Gene Symbol

VSIR

UniProt

Additional VISTA/B7-H5/PD-1H Products

Product Documents for Recombinant Human VISTA/B7-H5/PD-1H Fc Chimera Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human VISTA/B7-H5/PD-1H Fc Chimera Protein, CF

For research use only

Loading...
Loading...
Loading...